List of Excipients in Branded Drug NYMALIZE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Arbor Pharmaceuticals	NYMALIZE	nimodipine	24338-200	ALCOHOL
Arbor Pharmaceuticals	NYMALIZE	nimodipine	24338-200	GLYCERIN
Arbor Pharmaceuticals	NYMALIZE	nimodipine	24338-200	METHYLPARABEN

Nymalize Excipient Strategy and Commercial Opportunities: Nimodipine Oral Solution Patent and Product Analysis

Last updated: August 27, 2026

Nymalize is a 3 mg/mL oral solution of nimodipine approved for reducing the incidence and severity of neurological deficits associated with subarachnoid hemorrhage. Its commercial differentiation depends on liquid dosing, rapid administration through an enteral route, and avoidance of the formulation and administration errors associated with nimodipine capsules. The largest excipient opportunities are ethanol reduction or replacement, improved palatability, enteral-tube compatibility, unit-dose packaging, and differentiated hospital supply formats.

The principal competitive risk is generic or alternative oral nimodipine entry. Because Nymalize is a small-molecule product, biosimilar risk is not applicable. Formulation patents and regulatory exclusivity, rather than biologic manufacturing complexity, are the main barriers to competition.

What is Nymalize and how does its formulation work?

Nymalize contains nimodipine at a concentration of 3 mg/mL. The labeled dose is 60 mg, administered as 20 mL every four hours for 21 consecutive days, beginning within 96 hours of subarachnoid hemorrhage [1].

Product attribute	Nymalize specification
Active ingredient	Nimodipine
Dosage form	Oral solution
Concentration	3 mg/mL
Standard dose	60 mg, or 20 mL
Dosing frequency	Every four hours
Treatment duration	21 days
Primary indication	Reduction of neurological deficits after subarachnoid hemorrhage
Route	Oral or through a nasogastric tube
FDA approval	May 2013
NDA	203340

Nymalize replaced the need to extract liquid from nimodipine capsules. The FDA labeling specifically warns that nimodipine must not be administered intravenously or by another parenteral route because serious cardiovascular consequences and death can result [1].

The formulation contains ethanol, glycerin, sodium citrate dihydrate, citric acid, peppermint flavor, sucralose, and purified water, according to the prescribing information [1].

What excipients are used in Nymalize?

Nymalize uses a mixed solvent, buffering, sweetening, and flavor system.

Excipient	Functional role	Commercial or technical relevance
Ethanol	Solvent and cosolvent for nimodipine	Main safety, labeling, supply-chain, and differentiation issue
Glycerin	Cosolvent, humectant, viscosity modifier	Supports solubilization and mouthfeel
Sodium citrate dihydrate	Buffer component	Helps control pH and stability
Citric acid	Acidifying and buffer component	Controls pH and contributes to taste
Peppermint flavor	Taste masking	May limit patient acceptance in sensitive populations
Sucralose	High-intensity sweetener	Masks bitterness but may not eliminate solvent-related taste
Purified water	Primary vehicle	Supports oral liquid delivery

Nimodipine has poor aqueous solubility. The presence of ethanol and glycerin is therefore central to maintaining drug concentration in a small-volume liquid dosage form. A replacement excipient must preserve solubility, chemical stability, dose uniformity, microbial quality, and compatibility with enteral tubes.

What is the commercial role of ethanol in Nymalize?

Ethanol is the most commercially consequential excipient in Nymalize. The product contains a substantial quantity of alcohol per dose, and the label warns about alcohol exposure and administration risks [1].

For a 20 mL dose, the amount of ethanol is material from a medication-safety perspective. Relevant concerns include:

• Neonatal, pediatric, geriatric, hepatic, or alcohol-sensitive patients.
• Patients receiving other ethanol-containing medicines.
• Intensive-care patients with prolonged exposure over 21 days.
• Hospital policies limiting alcohol-containing oral liquids.
• Labeling and procurement requirements for controlled or hazardous excipient handling.
• Taste and tolerability.
• The risk that healthcare professionals may select an inappropriate administration route.

An ethanol-reduced formulation could create a meaningful product position if it maintains the same nimodipine concentration and dosing schedule. The strongest commercial claim would be operational and safety-related: lower alcohol exposure without sacrificing enteral usability or dose flexibility.

What excipient strategies could improve Nymalize?

Ethanol-reduced or ethanol-free formulation

The highest-value reformulation strategy is to replace part or all of the ethanol with a nonvolatile solvent or solubilization system. Candidate approaches include:

• Propylene glycol, subject to population-specific toxicology review.
• Polyethylene glycol systems.
• Additional glycerin or other polyols.
• Cyclodextrin complexes.
• Surfactant-assisted solubilization.
• Lipid-based or self-emulsifying systems.
• Amorphous or nanostructured nimodipine dispersions.
• pH-controlled systems, if adequate stability can be demonstrated.

An ethanol-free product would face a higher technical burden because nimodipine precipitation, adsorption, and dose nonuniformity could become critical. The formulation must remain homogeneous through storage and administration. Any replacement that increases viscosity could impair delivery through small-bore nasogastric tubes.

Improved taste and mouthfeel

Nymalize already uses peppermint flavor and sucralose. Commercial opportunities remain in:

• Lower-intensity or neutral flavor systems.
• Dual flavor options for hospital and outpatient use.
• Bitter-blocking technologies.
• Reduced sweetness.
• Lower viscosity.
• Smaller dose volume through higher concentration, if stability and safety support the change.

Taste improvement has greater value in outpatient continuation therapy than in sedated or intubated hospital patients. A hospital-focused product should prioritize tube performance, dose accuracy, and medication safety over consumer-oriented flavor claims.

Enteral-tube optimization

Nymalize is administered through a nasogastric tube when necessary. A differentiated formulation could target:

• Reduced tube adsorption.
• Lower residue after flushing.
• Reduced foaming.
• Compatibility with polyurethane and silicone tubes.
• Clear administration instructions for different tube diameters.
• Ready-to-administer unit-dose syringes.
• Barcode-enabled packaging.

Tube compatibility data can support hospital formulary adoption even when the active ingredient is not clinically differentiated.

Unit-dose packaging

A 20 mL unit-dose oral syringe would match the standard 60 mg dose and reduce bedside measurement errors. Packaging opportunities include:

• Premeasured oral syringes.
• Blistered or pouch-protected syringes.
• Tamper-evident unit doses.
• Integrated oral and enteral administration labeling.
• Cartons organized by the 21-day treatment course.
• Barcoded hospital doses.

The packaging strategy could be protected through design, use, or combination patents, although packaging claims are generally more vulnerable to design-around than composition claims.

What patents protect Nymalize?

Nymalize's relevant intellectual-property position is expected to center on nimodipine liquid compositions, excipient combinations, concentration, stability, and methods of administration. The key patent records must be evaluated in the current FDA Orange Book, USPTO Patent Center, and assignment records because listed patents, ownership, terminal disclaimers, and expiration dates can change through prosecution or legal events [2,3].

A formulation patent associated with Nymalize has been publicly identified as U.S. Patent No. 8,709,508. Its commercial significance is that a competitor may need to design around the claimed liquid composition or challenge the patent through an abbreviated new drug application containing a Paragraph IV certification. The enforceability analysis depends on the issued claims, prosecution history, terminal disclaimer status, maintenance fees, and any applicable pediatric extension.

What formulation claims matter most?

The strongest claim categories typically include:

1. A defined nimodipine concentration in a liquid vehicle.
2. A solvent system containing ethanol and glycerin.
3. Buffering components controlling formulation pH.
4. Flavor and sweetener combinations.
5. Stability or precipitation limitations.
6. A method of administering nimodipine orally or through an enteral tube.
7. A composition that avoids capsule manipulation.

Composition claims are generally more valuable than narrow flavor claims. A broad claim covering the solvent system can create a meaningful barrier to an ANDA, while a narrow flavor or packaging claim may be easier to avoid.

What is the Orange Book status of Nymalize?

Nymalize is an NDA product and may have listed patents and regulatory exclusivity associated with its approval. The Orange Book is the controlling public source for current patent listings, use codes, expiration dates, and exclusivity information [2].

The FDA approval date was May 10, 2013. Any five-year new-chemical-entity exclusivity would have run from approval, subject to the statutory framework and applicable extensions. The commercial protection today is therefore more likely to depend on patent rights, product differentiation, hospital adoption, and the absence or timing of approved ANDAs than on unexpired NCE exclusivity.

When does Nymalize lose exclusivity?

Nymalize does not have a single practical loss-of-exclusivity date unless the relevant Orange Book listings and patent terms are considered together. The key dates are:

Protection category	Relevance to Nymalize
Five-year NCE exclusivity	Tied to the 2013 FDA approval and generally no longer the principal barrier
Formulation patents	May delay or complicate ANDA approval
Method-of-use patents	Can affect labeling and use-code strategy
Pediatric extension	Applies only if granted and attached to an eligible patent or exclusivity period
FDA approval barriers	May remain relevant if no therapeutically equivalent liquid product is approved
Trade secrets	May protect manufacturing know-how but do not block independent development

A generic manufacturer could pursue an ANDA if it can demonstrate pharmaceutical equivalence, bioequivalence where required, and compliance with applicable patent certifications. A 505(b)(2) applicant could pursue a reformulated nimodipine liquid, particularly if the product differs in excipient system, concentration, dosing device, or administration profile.

Which companies are challenging Nymalize?

Publicly visible commercial risk should be assessed through FDA ANDA approvals, Paragraph IV litigation filings, Orange Book certifications, and 505(b)(2) applications. Nymalize is a small-molecule liquid product, so potential challengers include generic manufacturers with existing oral-liquid manufacturing capability and specialty companies selling hospital injectable or enteral products.

No biosimilar company is relevant because nimodipine is a chemically synthesized small molecule. A generic challenger would likely focus on:

• A lower-cost oral solution.
• An oral liquid with a different solvent system.
• A capsule product accompanied by a liquid-administration device.
• A concentrated solution with a smaller dose volume.
• A hospital-packaged product with unit-dose syringes.

The absence of a widely used equivalent liquid product can create a stronger commercial position than the active ingredient's age would suggest. The barrier is practical formulation development, not clinical novelty.

What Paragraph IV risks exist for Nymalize?

A Paragraph IV challenger would likely argue that the listed formulation claims are invalid, not infringed, or both. The most probable technical arguments would concern:

• Obviousness based on known nimodipine solubility systems.
• Predictability of combining ethanol, glycerin, buffers, sweeteners, and flavor.
• Lack of written description for broad excipient ranges.
• Design-around using a different cosolvent or complexation technology.
• Noninfringement based on excipient concentration or pH differences.
• Lack of meaningful unexpected results over prior liquid formulations.

The patent holder's strongest response would depend on demonstrated stability, reduced precipitation, dose uniformity, enteral-tube performance, or administration-safety advantages that were not predictable from the prior art.

A generic launch could occur through several scenarios:

Launch scenario	Commercial effect
No patent challenge	Entry waits for patent and regulatory barriers to clear
Paragraph III certification	Generic approval is deferred until listed patent expiry
Paragraph IV challenge with litigation	Approval timing depends on litigation and 30-month stay issues
Noninfringing reformulation	Earlier entry may be possible through 505(b)(2) or a different ANDA strategy
Capsule substitution	Partial price pressure but limited direct substitution where liquid dosing is required

What FDA regulatory pathways apply to Nymalize reformulation?

A reformulated nimodipine product could use one of three principal pathways.

ANDA

An ANDA is appropriate for a product that is pharmaceutically equivalent and bioequivalent to the reference listed drug. A materially different excipient system may complicate sameness and bioequivalence determinations, particularly for a liquid product where formulation changes can alter absorption.

505(b)(2)

A 505(b)(2) application is more suitable for an ethanol-free formulation, new concentration, revised dosing device, new administration route, or other change that relies partly on FDA findings for nimodipine but contains new supporting data.

Supplemental NDA

The existing sponsor could file a supplemental application for a manufacturing, packaging, or formulation change. The required supplement category would depend on the extent of the change and its effect on safety, efficacy, stability, and labeling.

An ethanol-free formulation would probably have the clearest regulatory-commercial value but also the largest development burden.

How strong is the Nymalize patent estate?

The estate is potentially strongest where claims cover the complete liquid composition rather than individual excipients. Its practical strength depends on claim breadth and whether a competitor can preserve nimodipine solubility using an alternative solvent or delivery technology.

Patent-estate factor	Assessment
Active ingredient novelty	Low; nimodipine is an established molecule
Liquid dosage-form differentiation	Moderate to high
Excipient-combination protection	Potentially meaningful
Manufacturing know-how	Can add a barrier but is difficult to enforce against independent development
Method-of-use protection	Narrower than composition protection
Generic design-around risk	Moderate
Biosimilar barrier	Not applicable
Hospital switching barrier	Moderate because of dosing and administration workflow

The most defensible commercial position combines patent protection with hospital implementation advantages. A competitor must match not only the active ingredient but also liquid stability, enteral delivery, dosing accuracy, packaging, and medication-safety performance.

What manufacturing and intellectual-property barriers affect competitors?

Manufacturing barriers include:

• Maintaining a clear, homogeneous solution at 3 mg/mL.
• Controlling precipitation during long-term and accelerated storage.
• Managing ethanol evaporation and container closure integrity.
• Ensuring consistent flavor and sweetener distribution.
• Preventing adsorption to dosing syringes and enteral tubes.
• Validating microbial control in a nonsterile oral liquid.
• Producing accurate unit-dose syringes at hospital scale.
• Demonstrating compatibility with common feeding tubes.

A competitor that removes ethanol may face new challenges in preservative strategy, solubility, viscosity, and container compatibility. A competitor that retains ethanol may avoid some development risk but lose differentiation on excipient safety and institutional procurement.

What commercial opportunities exist for Nymalize?

The most attractive opportunities are formulation and delivery improvements rather than new clinical indications.

Priority opportunity matrix

Opportunity	Patient or buyer value	Development difficulty	Commercial priority
Ethanol-reduced formulation	High	High	Very high
Ethanol-free formulation	High	Very high	High
Ready-to-administer 20 mL syringe	High	Low to moderate	Very high
Enteral-tube compatibility package	Moderate to high	Moderate	High
Improved taste	Moderate	Moderate	Medium
Higher concentration and lower volume	Moderate	High	Medium
21-day course packaging	High for hospitals	Low	High
Pediatric or alcohol-sensitive labeling strategy	Potentially high	High	Selective
International reformulation	Market-dependent	High	Selective

The strongest near-term opportunity is a hospital-ready presentation that combines the existing formulation with prefilled oral syringes, barcode labeling, a 21-day course package, and explicit enteral-tube instructions. This approach could generate value without exposing the sponsor to the technical risk of replacing ethanol.

The strongest long-term opportunity is an ethanol-free or substantially ethanol-reduced product protected by a new composition patent and supported through a 505(b)(2) application.

How does Nymalize compare with generic nimodipine capsules?

Attribute	Nymalize	Nimodipine capsule
Dosage form	Oral solution	Capsule
Dose measurement	Flexible by volume	Fixed capsule strength
Enteral administration	Designed for oral or NG use	Requires manipulation or alternative procedure
Solvent exposure	Contains ethanol	No liquid solvent exposure
Hospital medication-safety profile	Ready-to-administer liquid	Greater risk of improper capsule handling
Taste	Relevant	Limited
Formulation complexity	High	Lower
Generic substitution risk	Depends on liquid ANDA availability	Stronger in capsule market
Main differentiation	Administration and workflow	Lower-cost established dosage form

Nymalize's commercial value is highest when a patient cannot safely swallow capsules or when hospital staff need a standardized enteral liquid. Its value is lower where capsule administration is straightforward and institutions prioritize acquisition cost.

Key Takeaways

• Nymalize is a 3 mg/mL nimodipine oral solution approved in 2013 for subarachnoid hemorrhage.
• Its core excipient system uses ethanol, glycerin, citrate buffering, peppermint flavor, sucralose, and purified water.
• Ethanol is the principal excipient-related commercial weakness and the clearest reformulation opportunity.
• Prefilled 20 mL oral syringes and 21-day treatment-course packaging offer lower-risk hospital opportunities.
• An ethanol-free product could support a differentiated 505(b)(2) strategy but would require substantial solubility, stability, and tube-compatibility work.
• Nymalize faces generic rather than biosimilar risk.
• The relevant IP analysis should focus on liquid-composition claims, concentration, solvent ranges, method-of-use claims, and current Orange Book listings.
• Generic entry could occur through Paragraph III, Paragraph IV, or a noninfringing reformulated product.
• Hospital workflow, administration safety, and enteral-tube performance may provide stronger practical protection than the age of nimodipine itself.

FAQs About Nymalize Excipients and Commercial Strategy

Does Nymalize contain alcohol?

Yes. Nymalize contains ethanol as an inactive ingredient. The ethanol supports nimodipine solubilization but creates safety, labeling, taste, and procurement considerations.

Can Nymalize be reformulated without ethanol?

Potentially, but the replacement system must preserve nimodipine solubility, dose uniformity, stability, and enteral-tube performance. A materially different product may require a 505(b)(2) regulatory pathway.

Is Nymalize protected by a patent on nimodipine itself?

No. Nimodipine is an established active ingredient. Commercial protection is more likely to depend on formulation, administration, packaging, regulatory, and manufacturing rights.

Would a generic nimodipine capsule directly replace Nymalize?

Not in every clinical setting. Nymalize is designed for liquid oral or nasogastric administration, while capsules may be unsuitable for patients who cannot swallow or for standardized enteral delivery.

What is the most valuable new product concept based on Nymalize?

The highest-value concept is an ethanol-reduced or ethanol-free nimodipine oral solution supplied in prefilled, barcode-enabled 20 mL oral syringes with validated nasogastric-tube compatibility.

References

1. U.S. Food and Drug Administration. (2023). Nymalize (nimodipine) oral solution prescribing information. Arbor Pharmaceuticals, LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

4. U.S. Food and Drug Administration. (2013). Nymalize approval letter and regulatory review materials for NDA 203340. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/